Brazil's MoH partners with Merck Serono to invest $430 million in bio-pharma production

8 November 2013

The Brazilian Ministry of Health is managing a series of product development partnerships and the selection processes of new partners in order to attract more investments from multinational companies in Brazil's national healthcare system, reports Juliane Carvalho of Brazil Pharma News.

An agreement signed between Merck Serono, part of Germany’s Merck KGaA (MRK: DE) and Bionovis, a brazilian biopharmaceutical company founded in 2012 by a joint venture formed by Ache, EMS, Hypermarcas and Uniao Química, and authorized by the Ministry of Health will boost the Product Development Partnerships (PDPs) for national production of bio-pharmaceutical drugs.

To invest in biologic manufacturing facility

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK